On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

Kayani M, Murphy L, Dutey-Magni P, Howlett S, Sachdeva A, Padden-Modi M, Abdel-Aty H, Brown LC, Amos CL, Chan K, Gilbert DC, Langley RE, Brown M, Sydes MR, Parker CC, STAMPEDE Collaborators, Cross W, Malik Z, Varughese M, Turco F, Millman R, Matheson D, Gillessen S, Clarke NW, Parmar MKB, James ND, Attard G

Open source

DOI: 10.1016/s1470-2045(26)00066-5
Published: 2026 May
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00066-5,
  title = {On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.},
  author = {Kayani M and Murphy L and Dutey-Magni P and Howlett S and Sachdeva A and Padden-Modi M and Abdel-Aty H and Brown LC and Amos CL and Chan K and Gilbert DC and Langley RE and Brown M and Sydes MR and Parker CC and STAMPEDE Collaborators and Cross W and Malik Z and Varughese M and Turco F and Millman R and Matheson D and Gillessen S and Clarke NW and Parmar MKB and James ND and Attard G},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00066-5},
  url = {https://doi.org/10.1016/s1470-2045(26)00066-5}
}

RIS

TY  - JOUR
TI  - On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
AU  - Kayani M
AU  - Murphy L
AU  - Dutey-Magni P
AU  - Howlett S
AU  - Sachdeva A
AU  - Padden-Modi M
AU  - Abdel-Aty H
AU  - Brown LC
AU  - Amos CL
AU  - Chan K
AU  - Gilbert DC
AU  - Langley RE
AU  - Brown M
AU  - Sydes MR
AU  - Parker CC
AU  - STAMPEDE Collaborators
AU  - Cross W
AU  - Malik Z
AU  - Varughese M
AU  - Turco F
AU  - Millman R
AU  - Matheson D
AU  - Gillessen S
AU  - Clarke NW
AU  - Parmar MKB
AU  - James ND
AU  - Attard G
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00066-5
UR  - https://doi.org/10.1016/s1470-2045(26)00066-5
ER  -

APA

M, K., L, M., P, D., S, H., A, S., M, P., H, A., LC, B., CL, A., K, C., DC, G., RE, L., M, B., MR, S., CC, P., Collaborators, S., W, C., Z, M., M, V., F, T., R, M., D, M., S, G., NW, C., MKB, P., ND, J., & G, A. (2026). On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00066-5

Source records

pubmed · retrieved 2026-09-27T07:07:00.183Z
europe-pmc · retrieved 2026-09-27T07:07:00.185Z